Judit Boda‐Heggemann
Heidelberg University, University Medical Centre Mannheim, University Hospital Heidelberg
Papers
6
Total Citations
230
H-Index
5
About
Judit Boda-Heggemann is a leading radiation oncologist whose research centers on stereotactic body radiotherapy (SBRT) for liver oligometastases and cardiac radioablation. Her major contributions include pioneering active motion-compensation techniques for liver SBRT, which have dramatically improved treatment accuracy and local control rates. Through her leadership in the German Society for Radiation Oncology (DEGRO) SBRT database initiative, she co-authored a landmark 2018 study analyzing patterns of care across 474 patients with 623 liver metastases—a work cited over 150 times that established evidence-based benchmarks for the field. Boda-Heggemann has also developed innovative methods to correlate post-therapeutic MRI morphologic alterations with planned radiation doses, enabling in-vivo verification of treatment delivery. Her multi-platform pooled analyses consistently demonstrate excellent local control for liver oligometastases, while her recent involvement in the RAVENTA trial extends her expertise to cardiac radioablation for ventricular tachycardia. With multiple publications tracking long-term liver tissue changes after SBRT, her work provides critical insights for optimizing multimodal treatment regimens. Her research bridges cutting-edge imaging, motion management, and clinical outcomes, making her a pivotal figure in advancing precision radiotherapy.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6